Other cyclin-dependent kinases (Other CDKs)

Other cyclin-dependent kinases (CDKs) represent a diverse group of serine/threonine kinases that function beyond the traditional cell-cycle control roles of CDK1, 2, 4, and 6. This category primarily includes transcriptional CDKs such as CDK7, 8, 9, 12, and 13, which regulate RNA polymerase II activity and gene expression (Nature Reviews Drug Discovery, 2022). It also encompasses atypical members like CDK5, which is essential for neuronal architecture and synaptic plasticity (Frontiers in Molecular Neuroscience, 2021). In oncology, these kinases are increasingly targeted to exploit "transcriptional addiction" in cancer cells or to induce a "BRCAness" phenotype by inhibiting DNA damage response genes (Journal of Clinical Investigation, 2019). This strategy can sensitize tumors to other treatments, such as PARP inhibitors. Beyond cancer, members like CDK5 are significant targets in neurodegeneration due to their role in tau hyperphosphorylation in Alzheimer's disease (Molecular Neurobiology, 2020). Therapeutic strategies include small-molecule ATP-competitive inhibitors, covalent inhibitors, and emerging modalities like PROTACs. However, the high structural homology between family members poses a significant challenge for selectivity, often leading to dose-limiting toxicities such as myelosuppression and gastrointestinal distress (Cell Death & Disease, 2021). Successful clinical application depends on identifying specific biomarkers, such as CDK12 mutations or RNA polymerase II phosphorylation status, to select responsive patient populations.

Other names

Non-canonical cyclin-dependent kinasesTranscriptional CDKsAtypical CDKsCDK5CDK7CDK8CDK9CDK10CDK11CDK12CDK13CDK14CDK15CDK16CDK17CDK18CDK19CDK20

Inhibition of the catalytic activity of non-canonical cyclin-dependent kinases by competing with ATP for the binding site or through covalent modification, thereby disrupting downstream signaling, transcription, or DNA repair (Nature, 2020).